Arturo Molina - Mar 13, 2025 Form 4 Insider Report for Protagonist Therapeutics, Inc (PTGX)

Role
Chief Medical Officer
Signature
/s/ Matthew Gosling, Attorney-in-Fact for Arturo Molina, MD
Stock symbol
PTGX
Transactions as of
Mar 13, 2025
Transactions value $
-$953,894
Form type
4
Date filed
3/14/2025, 06:21 PM
Previous filing
Jan 17, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTGX Common Stock Options Exercise $666K +28.4K +33.9% $23.42 112K Mar 13, 2025 Direct
transaction PTGX Common Stock Options Exercise $81K +2.08K +1.85% $38.98 114K Mar 13, 2025 Direct
transaction PTGX Common Stock Sale -$1.7M -30.5K -26.67% $55.74 83.9K Mar 13, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTGX Stock Option (right to buy) Options Exercise $0 -28.4K -29.17% $0.00 69.1K Mar 13, 2025 Common Stock 28.4K $23.42 Direct F2
transaction PTGX Stock Option (right to buy) Options Exercise $0 -2.08K -4.17% $0.00 47.8K Mar 13, 2025 Common Stock 2.08K $38.98 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.245 to $56.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F2 The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.
F3 The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.